ALLK Sep 2024 2.000 call
| Previous close | 0.1200 |
| Open | 0.1300 |
| Bid | 0.0000 |
| Ask | 1.0000 |
| Strike | 2.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.1200 - 0.1300 |
| Contract range | N/A |
| Volume | |
| Open interest | 81 |
GlobeNewswireAllakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy –– AK006 was well-tolerated with a favorable safety profile – SAN CARLOS, Calif., June 25, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced positive results from the single and multiple asc
- GlobeNewswire
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chronic spontaneous urticaria (CSU) has been dosed in a randomized, double-blind, placebo-controlled Phase 1 trial of AK006. The Phase 1 trial is designed to assess the safety, tolerability and pharmacokinetics of AK006, and t
- GuruFocus.com
Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions
Detailed Analysis of Financial Performance and Future Outlook
